Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 21 2017 - 8:30AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of
therapeutics that target galectin proteins, announced today that
the Company will release fourth quarter and full year 2016 results
before the market opens on Tuesday, March 28, 2017. A copy of the
earnings release will be available on the investor relations
portion of the Company’s website at:
http://galectintherapeutics.com/.
Management will provide a business update and
conduct a question and answer session via a conference call
beginning at 9:00 a.m. ET, Tuesday, March 28, 2017.
To access the conference call dial 844-899-6544 and
provide the operator with Pin Number 89964111.
Galectin also invites all interested parties to
listen to its conference call via webcast at
http://edge.media-server.com/m/p/exukm2jh. The webcast will also be
available on the investor relations portion of the Company’s
website at http://galectintherapeutics.com/. The webcast will be
archived on the Company’s website within two hours of the live
call.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing
novel therapies to improve the lives of patients with chronic liver
and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a
carbohydrate-based drug that inhibits the galectin-3 protein which
is directly involved in multiple inflammatory, fibrotic, and
malignant diseases. The lead development program is in
non-alcoholic steatohepatitis (NASH) with cirrhosis, the most
advanced form of NASH related fibrosis. This is the most common
liver disease and one of the largest drug development opportunities
available today. Additional development programs are in treatment
of severe atopic dermatitis, moderate-to-severe plaque psoriasis,
and in combination immunotherapy for advanced melanoma and other
malignancies. Galectin seeks to leverage extensive scientific and
development expertise as well as established relationships with
external sources to achieve cost-effective and efficient
development. Additional information is available at
www.galectintherapeutics.com.
Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024